Premium
Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin‐resistant Helicobacter pylori infection
Author(s) -
USHIYAMA ATSUSHI,
TANAKA KAZUO,
AIBA YUJI,
SHIBA TADAHIKO,
TAKAGI ATSUSHI,
MINE TETSUYA,
KOGA YASUHIRO
Publication year - 2003
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1046/j.1440-1746.2003.03102.x
Subject(s) - lactobacillus gasseri , clarithromycin , helicobacter pylori , probiotic , medicine , microbiology and biotechnology , in vivo , lactobacillus , antibiotics , biology , bacteria , gastroenterology , genetics
Backgrounds and Aim: Clarithromycin (CAM)‐resistant Helicobacter pylori sometimes offers serious problems with eradication by antibiotics. The aim of this study was to determine whether a probiotic can be an alternative therapy in CAM‐resistant Hp infection. Methods: The effects of Lactobacillus gasseri (strain OLL2716) on the growth of CAM‐susceptible and CAM‐resistant H. pylori and interleukin (IL)‐8 production provoked by these strains were examined by in vitro experiments. Moreover, mice were infected with these CAM‐susceptible or CAM‐resistant H. pylori , and were treated with CAM or L. gasseri . Results: In vitro experiments demonstrated that L. gasseri inhibited the growth of H. pylori and suppressed H. pylori ‐associated IL‐8 production. Such effects were noted in CAM‐resistant and CAM‐susceptible H. pylori . Similarly, in an in vivo model of H. pylori infection, H. pylori colonization was significantly decreased by L. gasseri . Conclusion: Therefore, L. gasseri was found to act as a probiotic in CAM‐resistant H. pylori infection.